On the public citation graph

(1 S )-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment

0 signed · 195 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archderm.140.9.1161-copenalex-snapshot
Multiple Axillary Papules—Quiz Case
inferredcites →https://doi.org/10.1002/chem.19960020515openalex-snapshot
Synthesis of Methyl 5′‐Thio‐α‐isomaltoside via an Acyclic Monothioacetal and its Behavior toward Glucoamylase
inferredcites →https://doi.org/10.1006/geno.1993.1411openalex-snapshot
Localization of the Na+/Glucose Cotransporter Gene SGLT2 to Human Chromosome 16 Close to the Centromere
inferredcites →https://doi.org/10.1007/pl00002934openalex-snapshot
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
inferredcites →https://doi.org/10.1016/0005-2736(82)90367-4openalex-snapshot
Phlorizin as a probe of the small-intestinal Na+,d-glucose cotransporter. A model
inferredcites →https://doi.org/10.1016/0006-2952(91)90435-8openalex-snapshot
Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas
inferredcites →https://doi.org/10.1016/0040-4039(93)88013-9openalex-snapshot
Unprecedented chemical glycosidation of 5-thioglucose to give disaccharides.
inferredcites →https://doi.org/10.1016/s0002-9343(96)00353-1openalex-snapshot
An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1016/s0008-6215(97)10041-6openalex-snapshot
Synthesis of 4-cyanophenyl 1,5-dithio-β-d-glucopyranoside and its 6-deoxy, as well as 6-deoxy-5-ene derivatives as oral antithrombotic agents
inferredcites →https://doi.org/10.1016/s0014-2999(00)00016-9openalex-snapshot
Antidiabetic effect of T-1095, an inhibitor of Na+-glucose cotransporter, in neonatally streptozotocin-treated rats
inferredcites →https://doi.org/10.1016/s0040-4039(01)92419-0openalex-snapshot
A novel synthesis of 5-thio--glucose
inferredcites →https://doi.org/10.1016/s0960-894x(03)00466-9openalex-snapshot
Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
inferredcites →https://doi.org/10.1021/ja00016a039openalex-snapshot
Enzyme-catalyzed aldol condensation for asymmetric synthesis of azasugars: synthesis, evaluation, and modeling of glycosidase inhibitors
inferredcites →https://doi.org/10.1021/ja00040a080openalex-snapshot
Chemical-enzymic synthesis of 5'-thio-N-acetyllactosamine: the first disaccharide with sulfur in the ring of the non-reducing sugar
inferredcites →https://doi.org/10.1021/jm00156a023openalex-snapshot
Synthesis and .alpha.-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents
inferredcites →https://doi.org/10.1021/jm0493156openalex-snapshot
(2 R )-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a ]pyrazin- 7(8 H )-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
inferredcites →https://doi.org/10.1021/jm701272qopenalex-snapshot
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
inferredcites →https://doi.org/10.1021/jm8013019openalex-snapshot
Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
inferredcites →https://doi.org/10.1021/jm900951nopenalex-snapshot
Novel l -Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes
inferredcites →https://doi.org/10.1021/jm990175nopenalex-snapshot
Na+-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4‘-Dehydroxyphlorizin Derivatives Substituted on the B Ring
inferredcites →https://doi.org/10.1021/js9803205openalex-snapshot
MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening
inferredcites →https://doi.org/10.1038/clpt.1982.54openalex-snapshot
The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses
inferredcites →https://doi.org/10.1038/sj.bjp.0703829openalex-snapshot
Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐glucose cotransporter inhibitor T‐1095
inferredcites →https://doi.org/10.1039/p19900002763openalex-snapshot
Synthesis of per-O-alkylated 5-thio-D-glucono-1,5-lactones and transannular participation of the ring sulphur atom of 5-thio-D-glucose derivatives on solvolysis under acidic conditions
inferredcites →https://doi.org/10.1074/jbc.270.49.29365openalex-snapshot
Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat Kidney
inferredcites →https://doi.org/10.1124/dmd.109.029165openalex-snapshot
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
inferredcites →https://doi.org/10.1124/jpet.106.110296openalex-snapshot
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
inferredcites →https://doi.org/10.1124/jpet.108.140210openalex-snapshot
Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models
inferredcites →https://doi.org/10.1152/ajprenal.2001.280.1.f10openalex-snapshot
Renal Na + -glucose cotransporters
inferredcites →https://doi.org/10.1152/physrev.1945.25.2.255openalex-snapshot
PHLORHIZIN GLUCOSURIA
inferredcites →https://doi.org/10.1152/physrev.1994.74.4.993openalex-snapshot
Molecular physiology of sodium-glucose cotransporters.
inferredcites →https://doi.org/10.1210/jc.2008-2291openalex-snapshot
Prevalence and Incidence of Endocrine and Metabolic Disorders in the United States: A Comprehensive Review
inferredcites →https://doi.org/10.1248/bpb.23.1434openalex-snapshot
Antihyperglycemic Effect of T-1095 via Inhibition of Renal Na+-Glucose Cotransporters in Streptozotocin-Induced Diabetic Rats.
inferredcites →https://doi.org/10.1248/cpb.39.1440openalex-snapshot
Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds.
inferredcites →https://doi.org/10.1517/13543770903337828openalex-snapshot
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
inferredcites →https://doi.org/10.1517/13543776.15.11.1531openalex-snapshot
Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents
inferredcites →https://doi.org/10.1517/13543784.12.1.87openalex-snapshot
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
inferredcites →https://doi.org/10.1517/14728222.9.4.861openalex-snapshot
Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases
inferredcites →https://doi.org/10.2337/db05-1602openalex-snapshot
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
inferredcites →https://doi.org/10.2337/diacare.21.9.1414openalex-snapshot
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4806674openalex-extracted
Concise and Efficient Synthesis of 5-Thioglucose and its Pentaacetatederivative
inferred← citeshttps://doi.org/10.1002/0471266949.bmc277openalex-snapshot
Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes
inferred← citeshttps://doi.org/10.1002/9781118905074.ch02openalex-snapshot
Protection for the Hydroxyl Group, Including 1,2‐ and 1,3‐Diols
inferred← citeshttps://doi.org/10.1002/9783527676545.ch09openalex-snapshot
From Natural Product to New Diabetes Therapy: Phlorizin and the Discovery of SGLT2 Inhibitor Clinical Candidates
inferred← citeshttps://doi.org/10.1002/9783527826872.ch4openalex-snapshot
Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
inferred← citeshttps://doi.org/10.1002/ardp.70127openalex-snapshot
An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies
inferred← citeshttps://doi.org/10.1002/bdd.1909openalex-snapshot
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
inferred← citeshttps://doi.org/10.1002/cjoc.202300308openalex-snapshot
C‐Aryl Glycosylation via Interrupted Pummerer Rearrangement†
inferred← citeshttps://doi.org/10.1002/cpdd.364openalex-snapshot
Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study
inferred← citeshttps://doi.org/10.1002/cpdd.456openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
inferred← citeshttps://doi.org/10.1002/ejoc.201500282openalex-snapshot
Sc(OTf)3‐Catalysed [3+3] Annulation of Cyclopropane 1,1‐Diesters with Mercaptoacetaldehyde: A Facile Strategy for the Synthesis of Tetrahydrothiopyranols
inferred← citeshttps://doi.org/10.1002/ejoc.201700503openalex-snapshot
Organocatalytic Asymmetric Synthesis of Tetrahydrothiophenes and Tetrahydrothiopyrans
inferred← citeshttps://doi.org/10.1002/ejoc.202000025openalex-snapshot
Synthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1002/fsn3.71621openalex-snapshot
Boscisucrophage: A Natural SGLT1 /2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes
inferred← citeshttps://doi.org/10.1002/med.21314openalex-snapshot
Ramping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure
inferred← citeshttps://doi.org/10.1007/7081_2015_166openalex-snapshot
Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s00044-024-03274-4openalex-snapshot
Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s00125-019-05071-wopenalex-snapshot
Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway
inferred← citeshttps://doi.org/10.1007/s00706-013-1053-0openalex-snapshot
A facile synthesis of 6-deoxydapagliflozin
inferred← citeshttps://doi.org/10.1007/s00894-011-1303-1openalex-snapshot
A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
inferred← citeshttps://doi.org/10.1007/s12020-024-03925-xopenalex-snapshot
Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s12325-014-0102-3openalex-snapshot
Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
inferred← citeshttps://doi.org/10.1007/s12325-015-0200-xopenalex-snapshot
Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
inferred← citeshttps://doi.org/10.1007/s12325-015-0209-1openalex-snapshot
Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
inferred← citeshttps://doi.org/10.1007/s40265-014-0230-8openalex-snapshot
Luseogliflozin: First Global Approval
inferred← citeshttps://doi.org/10.1007/s41061-019-0243-6openalex-snapshot
In the Search of Glycoside-Based Molecules as Antidiabetic Agents
inferred← citeshttps://doi.org/10.1016/b978-0-12-386009-5.00020-5openalex-snapshot
SGLT2 Inhibitors for Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12430-8openalex-snapshot
Sodium–Glucose Cotransporters
inferred← citeshttps://doi.org/10.1016/b978-0-12-809450-1.00005-3openalex-snapshot
Carbohydrate-Based Antidiabetic Agents From Nature∗∗This chapter is dedicated to Dr R P Tripathi, Senior Scientist at Central Drug Research Institute, Lucknow on the occasion of his 60th birthday celebration.
inferred← citeshttps://doi.org/10.1016/b978-0-12-816675-8.00003-8openalex-snapshot
Bioactive C-glycosides inspired from natural products towards therapeutics
inferred← citeshttps://doi.org/10.1016/b978-0-443-45775-3.00003-xopenalex-snapshot
Natural products with anti-type 2 diabetes mellitus activity and their structure–activity relationships
inferred← citeshttps://doi.org/10.1016/j.algal.2024.103610openalex-snapshot
Microalgae and cyanobacteria as natural sources of antioxidant enzymes and enzyme inhibitors for Alzheimer's and diabetes
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.05.020openalex-snapshot
Carbohydrate-based drugs launched during 2000−2021
inferred← citeshttps://doi.org/10.1016/j.bbamem.2015.08.001openalex-snapshot
Binding interaction of SGLT with sugar and thiosugar by the molecular dynamics simulation
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118210openalex-snapshot
Special focus on the mitochondria in endothelial cells: A novel therapeutic target for gliflozins?
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118837openalex-snapshot
Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review
inferred← citeshttps://doi.org/10.1016/j.bmc.2011.08.005openalex-snapshot
5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.bmc.2012.04.053openalex-snapshot
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.bmc.2013.08.067openalex-snapshot
Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmc.2016.03.004openalex-snapshot
Synthetic approaches to the 2014 new drugs
inferred← citeshttps://doi.org/10.1016/j.bmc.2018.12.015openalex-snapshot
Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment
inferred← citeshttps://doi.org/10.1016/j.bmcl.2011.04.053openalex-snapshot
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmcl.2012.09.049openalex-snapshot
Synthesis and anti-hyperglycemic activity of hesperidin derivatives
inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.01.016openalex-snapshot
Transporter-mediated tissue targeting of therapeutic molecules in drug discovery
inferred← citeshttps://doi.org/10.1016/j.bmcl.2018.04.070openalex-snapshot
Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmcl.2018.09.025openalex-snapshot
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmcl.2018.09.035openalex-snapshot
Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.bmcl.2021.128466openalex-snapshot
Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.129050openalex-snapshot
Lead identification of novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent heparanase-1 inhibitor
inferred← citeshttps://doi.org/10.1016/j.clinthera.2015.10.025openalex-snapshot
Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1016/j.ejmcr.2022.100074openalex-snapshot
A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
inferred← citeshttps://doi.org/10.1016/j.ejmech.2016.02.053openalex-snapshot
Synthesis and biological evaluation of novel tetrahydroisoquinoline- C -aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.04.061openalex-snapshot
Current anti-diabetic agents and their molecular targets: A review
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.07.032openalex-snapshot
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.111773openalex-snapshot
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116343openalex-snapshot
Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116364openalex-snapshot
The role of the methoxy group in approved drugs
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117248openalex-snapshot
Discovery of a highly potent, selective, and stable d-amino acid-containing peptide inhibitor of CDK9/cyclin T1 interaction for the treatment of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117977openalex-snapshot
SGLT2 inhibitors in translational medicine: A paradigm shift for diabetes and heart health
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.118707openalex-snapshot
Medicinal chemistry advances of SGLT inhibitors: SAR, structural innovation, and mechanistic insights
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174378openalex-snapshot
Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2023.108650openalex-snapshot
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
inferred← citeshttps://doi.org/10.1016/j.jmgm.2021.108106openalex-snapshot
Exploring sodium glucose cotransporter (SGLT2) inhibitors with machine learning approach: A novel hope in anti-diabetes drug discovery
inferred← citeshttps://doi.org/10.1016/j.jphs.2015.04.001openalex-snapshot
In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2013.04.003openalex-snapshot
Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
inferred← citeshttps://doi.org/10.1016/j.tet.2015.05.108openalex-snapshot
Synthesis of novel N-glycoside derivatives via CuSCN-catalyzed reactions and their SGLT2 inhibition activities
inferred← citeshttps://doi.org/10.1016/j.tet.2018.09.022openalex-snapshot
Cascade reactions as efficient and universal tools for construction and modification of 6-, 5-, 4- and 3-membered sulfur heterocycles of biological relevance
inferred← citeshttps://doi.org/10.1016/j.tet.2024.134164openalex-snapshot
Mild and practical synthesis of 5-thio-d-glucopyranose and its pentaacetate derivatives
inferred← citeshttps://doi.org/10.1016/j.tetlet.2012.02.062openalex-snapshot
Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
inferred← citeshttps://doi.org/10.1016/j.tetlet.2016.09.003openalex-snapshot
An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue
inferred← citeshttps://doi.org/10.1021/acs.chemrev.6b00475openalex-snapshot
C-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00867openalex-snapshot
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b01541openalex-snapshot
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b01818openalex-snapshot
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b01701openalex-snapshot
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
inferred← citeshttps://doi.org/10.1021/acs.joc.2c01610openalex-snapshot
Acetic Acid Mediated Regioselective [3 + 3] Cycloaddition of Substituted Cyclopropane-1,1-dicarbonitriles with 1,4-Dithiane-2,5-diol
inferred← citeshttps://doi.org/10.1021/acs.joc.6c00212openalex-snapshot
Bicyclic δ-Thiolactone Glycomimetics: Stereoselective Synthesis and Discovery of Stereocontrolled Antiphage Activity
inferred← citeshttps://doi.org/10.1021/acs.oprd.8b00017openalex-snapshot
Synthetic Strategies toward SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.oprd.8b00325openalex-snapshot
Process Development for a Locally Acting SGLT1 Inhibitor, LX2761, Utilizing sp 3 –sp 2 Suzuki Coupling of a Benzyl Carbonate
inferred← citeshttps://doi.org/10.1021/acs.orglett.2c00980openalex-snapshot
Efficient Route to Canagliflozin via Anhydroketopyranose
inferred← citeshttps://doi.org/10.1021/acs.orglett.6b00155openalex-snapshot
Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.orglett.6c01731openalex-snapshot
Lewis Acid-Catalyzed (3+3) Annulation of Bicyclo[1.1.0]butanes with Mercaptoacetaldehyde: Access to 2-Thiabicyclo[3.1.1]heptanes
inferred← citeshttps://doi.org/10.1021/acscatal.8b04686openalex-snapshot
Iridium-Catalyzed Direct Hydroarylation of Glycals via C–H Activation: Ligand-Controlled Stereoselective Synthesis of α- and β-C-Glycosyl Arenes
inferred← citeshttps://doi.org/10.1021/acsomega.2c06483openalex-snapshot
Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption
inferred← citeshttps://doi.org/10.1021/acsomega.3c01972openalex-snapshot
New Synthesis of Diarylmethanes, Key Building Blocks for SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1021/jm200049ropenalex-snapshot
Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors
inferred← citeshttps://doi.org/10.1021/jm300884kopenalex-snapshot
Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1021/ol4033557openalex-snapshot
Facile Assembly of Chiral Tetrahydrothiopyrans Containing Four Consecutive Stereocenters via an Organocatalytic Enantioselective Michael–Michael Cascade
inferred← citeshttps://doi.org/10.1038/s41598-022-13888-6openalex-snapshot
Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
inferred← citeshttps://doi.org/10.1038/s41598-024-76256-6openalex-snapshot
Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion
inferred← citeshttps://doi.org/10.1038/s42003-022-03605-4openalex-snapshot
Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects
inferred← citeshttps://doi.org/10.1039/c2md20163aopenalex-snapshot
On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin
inferred← citeshttps://doi.org/10.1039/c4np00064aopenalex-snapshot
Natural product and natural product derived drugs in clinical trials
inferred← citeshttps://doi.org/10.1039/c4ob01975jopenalex-snapshot
Palladium(0)-catalyzed synthesis of cyclic glucosides
inferred← citeshttps://doi.org/10.1039/c6ob00948dopenalex-snapshot
Catalytic asymmetric [3 + 3] annulation of cyclopropanes with mercaptoacetaldehyde
inferred← citeshttps://doi.org/10.1039/c7cc06800jopenalex-snapshot
Catalyst free annulative thioboration of unfunctionalized olefins
inferred← citeshttps://doi.org/10.1039/c8md00183aopenalex-snapshot
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
inferred← citeshttps://doi.org/10.1039/c9ra08706kopenalex-snapshot
SGLT inhibitors as antidiabetic agents: a comprehensive review
inferred← citeshttps://doi.org/10.1055/s-0036-1591736openalex-snapshot
Organocatalytic Asymmetric Synthesis of Pentasubstituted Tetrahydrothiopyrans Bearing a Quaternary Centre through a Double Michael Reaction
inferred← citeshttps://doi.org/10.1055/s-0042-1751524openalex-snapshot
Synthetic Approaches to Gliflozins: A Comprehensive Overview
inferred← citeshttps://doi.org/10.1080/00397911.2019.1666283openalex-snapshot
Facile and green synthesis of dapagliflozin
inferred← citeshttps://doi.org/10.1080/00498254.2016.1193913openalex-snapshot
In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor
inferred← citeshttps://doi.org/10.1080/1062936x.2021.1971295openalex-snapshot
QSAR analysis of sodium glucose co–transporter 2 (SGLT2) inhibitors for anti-hyperglycaemic lead development
inferred← citeshttps://doi.org/10.1080/14740338.2017.1359252openalex-snapshot
Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation
inferred← citeshttps://doi.org/10.1097/mnh.0b013e32833bec06openalex-snapshot
Sodium–glucose transport: role in diabetes mellitus and potential clinical implications
inferred← citeshttps://doi.org/10.1101/2023.01.23.524988openalex-snapshot
Structural insights into the mechanism of the human SGLT2–MAP17 glucose transporter
inferred← citeshttps://doi.org/10.1111/dom.12064openalex-snapshot
Inhibition of the sodium glucose co‐transporter‐2: its beneficial action and potential combination therapy for type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1111/dom.13630openalex-snapshot
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
inferred← citeshttps://doi.org/10.1111/j.1463-1326.2011.01517.xopenalex-snapshot
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
inferred← citeshttps://doi.org/10.1111/j.1476-5381.2011.01340.xopenalex-snapshot
TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
inferred← citeshttps://doi.org/10.1111/jcpt.12077openalex-snapshot
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
inferred← citeshttps://doi.org/10.1111/jdi.12214openalex-snapshot
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
inferred← citeshttps://doi.org/10.1124/dmd.114.058305openalex-snapshot
A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans
inferred← citeshttps://doi.org/10.1124/jpet.112.191593openalex-snapshot
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
inferred← citeshttps://doi.org/10.1124/jpet.113.203869openalex-snapshot
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
inferred← citeshttps://doi.org/10.1152/ajprenal.00005.2024openalex-snapshot
SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
inferred← citeshttps://doi.org/10.1152/ajprenal.00119.2025openalex-snapshot
Gliflozins in hypertension: basic mechanisms and clinical insights
inferred← citeshttps://doi.org/10.1185/03007995.2014.901943openalex-snapshot
Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
inferred← citeshttps://doi.org/10.1185/03007995.2014.909390openalex-snapshot
Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
inferred← citeshttps://doi.org/10.1185/03007995.2014.912983openalex-snapshot
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
inferred← citeshttps://doi.org/10.1186/s13098-015-0102-8openalex-snapshot
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
inferred← citeshttps://doi.org/10.1186/s13098-019-0454-6openalex-snapshot
Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
inferred← citeshttps://doi.org/10.1248/bpb.b16-00998openalex-snapshot
Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1254/fpj.148.253openalex-snapshot
SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications
inferred← citeshttps://doi.org/10.1293/tox.2015-0054openalex-snapshot
Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study
inferred← citeshttps://doi.org/10.1371/journal.pone.0139873openalex-snapshot
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
inferred← citeshttps://doi.org/10.14814/phy2.12436openalex-snapshot
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
inferred← citeshttps://doi.org/10.1517/13543784.2013.774372openalex-snapshot
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1517/14656566.2014.978290openalex-snapshot
Luseogliflozin for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1517/14728214.2013.831405openalex-snapshot
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3207194/v1openalex-snapshot
Antidiabetic Activity, Molecular Identification and In silico Docking of Compounds in Chromatographic Fractions of Tephrosia bracteolata Guill. & Perr. (Fabaceae) Leaves
inferred← citeshttps://doi.org/10.2174/1389557521666210805112416openalex-snapshot
Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.2174/1573399817666210917122745openalex-snapshot
Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes
inferred← citeshttps://doi.org/10.2174/1573406411666150105105529openalex-snapshot
Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry
inferred← citeshttps://doi.org/10.2174/1871530323666230522112758openalex-snapshot
An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets
inferred← citeshttps://doi.org/10.2337/db12-0052openalex-snapshot
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
inferred← citeshttps://doi.org/10.2337/dc15-0642openalex-snapshot
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
inferred← citeshttps://doi.org/10.26538/tjnpr/v9i8.31openalex-snapshot
Antidiabetic Activity and in silico Molecular Docking of GC-MS- Identified Compounds in Chromatographic Fractions of Tephrosia bracteolata Guill. & Perr. (Fabaceae) Leaves
inferred← citeshttps://doi.org/10.3109/00498254.2015.1042947openalex-snapshot
Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent
inferred← citeshttps://doi.org/10.33263/lianbs152.060openalex-snapshot
In Silico Drug-Likeness/ADME-T Studies and Molecular Docking of Compounds from Tephrosia bracteolata Leaves against some Targets of Diabetic Complications
inferred← citeshttps://doi.org/10.3389/fphar.2026.1776423openalex-snapshot
Discovery of potent and highly selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for treating diabetic nephropathy
inferred← citeshttps://doi.org/10.3390/cells12182221openalex-snapshot
Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
inferred← citeshttps://doi.org/10.3390/ijms18081704openalex-snapshot
The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
inferred← citeshttps://doi.org/10.3390/ijms23105634openalex-snapshot
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
inferred← citeshttps://doi.org/10.3390/molecules30244681openalex-snapshot
Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential
inferred← citeshttps://doi.org/10.3390/ph14040364openalex-snapshot
Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors
inferred← citeshttps://doi.org/10.4018/979-8-3693-7267-8.ch002openalex-snapshot
Bioactive Pyrazoles
inferred← citeshttps://doi.org/10.4155/bio-2016-0188openalex-snapshot
A Simple and Rapid LC–MS/MS Method for Quantitation of Luseogliflozin in Rat Plasma and its Application to A PK Study
inferred← citeshttps://doi.org/10.4155/fmc-2017-0241openalex-snapshot
Recent Progress of Sodium-Glucose Transporter 2 Inhibitors as Potential Antidiabetic Agents
inferred← citeshttps://doi.org/10.4155/fmc-2020-0154openalex-snapshot
SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
inferred← citeshttps://doi.org/10.4239/wjd.v6.i1.136openalex-snapshot
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
inferred← citeshttps://doi.org/10.5059/yukigoseikyokaishi.74.949openalex-snapshot
Construction of C-glucoside in SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.52590/m3.p709.a30002770openalex-snapshot
Empagliflozina, Inibidor do SGLT2 no Tratamento da Diabetes do Tipo 2
inferred← citeshttps://doi.org/10.5582/ddt.2024.01086openalex-snapshot
Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu)
inferred← citeshttps://doi.org/10.5772/23463openalex-snapshot
Carbohydrate Derivatives and Glycomimetic Compounds in Established and Investigational Therapies of Type 2 Diabetes Mellitus
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.